Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
about
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversiesMultidisciplinary management of nonfunctional neuroendocrine tumor of the pancreasUpdate on surgical treatment of pancreatic neuroendocrine neoplasmsPET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literatureManagement of patients with hepatic metastases from neuroendocrine tumorsImaging of gastroenteropancreatic neuroendocrine tumorsNeuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsThe assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.Clinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from iranPrognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Therapy for metastatic pancreatic neuroendocrine tumors.Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.Multimodal management of neuroendocrine liver metastases.Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumorsRequiem for the term 'carcinoid tumour' in the gastrointestinal tract?Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resectionTransplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews.Diagnosis and prediction of neuroendocrine liver metastases: a protocol of six systematic reviews.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursTargeted therapy in advanced well-differentiated neuroendocrine tumors.Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinicaPredictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours.Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of ChinaTNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.Prognostic relevance of survivin in pancreatic endocrine tumorsPrognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experienceGene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyExtensive multiarterial resection attending total duodenopancreatectomy and adrenalectomy for MEN-1-associated neuroendocrine carcinomas.A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
P2860
Q24647838-106FEF06-7C5D-4E79-A9C7-C0BD55CFEB0FQ26752757-1DB54C93-F010-4493-85CA-0A468F0F2124Q26864361-5A5E9393-9FBF-4418-B076-74076A06C06EQ26992201-91EA86AB-0966-417D-B891-F942F5A6E825Q27008832-FFED126B-DAEC-4895-9C85-A23FD9B700E7Q28238305-9D7D54EA-C082-44AA-B5BB-53A39A92C7B6Q28285545-9ADD17B9-20C9-4DA8-A360-D13D0E7295B2Q28290833-5C657532-C759-4E9F-83A3-05842CDF742DQ30252003-DBD0AE57-F721-4D5D-9518-6DC354720F5EQ33417013-CB668311-441C-4ABC-86FE-BDB937A1123FQ33782024-E818038C-7B8E-4E1A-9161-105F20F32D5EQ33828850-BF5F9DF2-90B5-4C55-84AA-92E23CBCA2BDQ33901099-F928E55F-90C9-488D-9E9E-212C2B05BA53Q33993022-79F03945-7C92-496B-A5E4-8DDF71A3412BQ34090931-B34C9C36-A174-4A83-B73B-C8F3FE8B4AEEQ34248466-99D43C6D-DE41-4FCB-AEBF-BA8D219336B8Q34248487-C72D70CA-FA74-4A8B-8B21-71C57CC3AC47Q34357869-7E40DA4A-B430-4F10-8273-92A326A57A9CQ34446086-89B6B0BE-66D5-4C17-979F-6382066755B8Q34528199-D9FE35D5-E17D-4E2B-842D-C992140FA8ADQ34750730-FC00CB24-0BE4-4663-A599-40C3E111221AQ34770091-2F7DB58C-7639-4879-ADDE-16415F824F1AQ35034000-375F5FB6-3C6D-494B-9A0B-2643972D59BFQ35065094-FA9859F8-70A6-4369-8570-E46777D9458BQ35074937-655DD567-DE1E-42FD-8216-6677AFF3752DQ35074944-D9419029-30B2-48F3-B0E8-AC5EB1810BD4Q35274974-A2EA2B5F-EA78-407A-BBC7-5706C8A21C7BQ35584497-549CB62E-CA8E-4CF6-AB07-AA7B7A5FF013Q35640506-5CFB780F-7EEF-4D31-9477-890CB2DB3F67Q35658025-23E74465-928B-4C36-B63D-A033AED182CCQ35783628-9BF6960C-7DDC-473A-BCD4-2C15D0E8391BQ35812801-F49E4C70-34FF-42CE-A28F-C232700DFD6EQ35837124-B93226EF-EE8E-42D0-994C-DFB546984737Q35947272-D81834D3-D6AD-4DC2-8721-0902E546362AQ36178121-4A4CD179-DF0C-49DE-A934-B64FE365120DQ36335121-B0461BCF-A770-4DDC-83F4-B1128A2B148BQ36344419-13C1E82F-C5FD-42B2-B83C-FDE70FB09D42Q36413831-FF20FAD6-1EB0-405A-B12D-67F577765DAAQ36638258-C69A228E-F743-4330-AA49-7CA260D36739Q36857533-811B08FE-149F-4CE5-A497-8319C9966358
P2860
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
description
im Dezember 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 December 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2005
@uk
name
Prognostic factors and surviva ...... al and pancreatic localization
@en
Prognostic factors and surviva ...... al and pancreatic localization
@nl
type
label
Prognostic factors and surviva ...... al and pancreatic localization
@en
Prognostic factors and surviva ...... al and pancreatic localization
@nl
prefLabel
Prognostic factors and surviva ...... al and pancreatic localization
@en
Prognostic factors and surviva ...... al and pancreatic localization
@nl
P2093
P50
P921
P356
P1476
Prognostic factors and surviva ...... al and pancreatic localization
@en
P2093
Cesare Bordi
Gianfranco Delle Fave
Maria Sofia Cattaruzza
Michela Di Fonzo
Paolo Pederzoli
Sara Cassetta
Silvia Nasoni
Stefano Angeletti
Valentina Tornatore
Vincenzo Ziparo
P304
P356
10.1677/ERC.1.01017
P577
2005-12-01T00:00:00Z